Pharmacally

Online/Digital
Pharmacally.com is your trusted source for accurate, up-to-date medical information and healthcare insights. As the official platform of MedCognize Communications Pvt. Ltd., OPC we aim to empower patients, caregivers, and healthcare professionals with the knowledge to make informed decisions and ensure quality care. We simplify complex medical topics covering conditions, new treatments, innovations, clinical trials, drug safety alerts, nutrition, and lifestyle into clear, evidence-based resources. Our focus is on patient safety, rights, and awareness, helping you navigates the healthcare system with confidence. By staying ahead of medical advancements and blending science with holistic health perspectives, we work to create a more informed, safe, and empowered healthcare community. Your health journey starts with knowledge, and we’re here to guide you every step of the way. Source

Actions

Share this page

Media Outlet details

Scope Trade/B2B
Language English
Country India
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Rezolute Presents New Ersodetug Analyses Following Mixed Phase 3 Results

| Pharmacally
Rezolute showcased additional ersodetug data at ENDO 2026, highlighting congenital hyperinsulinism burden and expanded access outcomes after the Phase 3 sunRIZE study missed its primary endpoint Written By: Shaik Yasmeen, PharmD Reviewed By: Pharmacally Editorial Team Rezolute presented four analyses at ENDO 2026 that further characterize the burden of congenital hyperinsulinism (HI) and provide additional evidence supporting ersodetug, the company’s investigational monoclonal antibody for...
Open in Who Shared Issue with article?

Suven’s Ropanicant Improves Depression Scores in Phase 2b Trial

| Pharmacally
Suven Life Sciences’ Ropanicant (SUVN‑911) met its primary endpoint in a Phase 2b trial for major depressive disorder, showing clinically meaningful MADRS improvement and favorable tolerability, supporting plans for a global Phase 3 program.
Open in Who Shared Issue with article?

Japan Expands Xocova Approval to Children Aged 6–11 Years With COVID-19

| Pharmacally
Japan has approved pediatric use of Xocova (ensitrelvir) for children aged 6–11 years weighing at least 20 kg, supported by Phase 3 data showing favorable safety and pharmacokinetic profiles. Written By: Disha Jadhao, BPharm Reviewed By: Pharmacally Editorial Team Shionogi has secured supplemental approval in Japan for the pediatric use of Xocova (ensitrelvir fumaric acid) in children aged 6 to under 12 years who weigh at least 20 kg, expanding access to the oral antiviral treatment for COVID-19.
Open in Who Shared Issue with article?

Suven’s SUVN-I6107 Shows Early Cognitive Benefits and CNS Activity in Phase 1 Study

| Pharmacally
Suven Life Sciences reported positive Phase 1 results for SUVN-I6107, a selective M1-PAM, demonstrating favorable safety, dose-proportional pharmacokinetics, and evidence of CNS activity, supporting advancement into Phase 2 studies. Written By: Kirti Kumbhar, M.
Open in Who Shared Issue with article?

Kither’s KIT2014 Advances as a Potential Dual-Action Therapy for Multiple Respiratory Diseases

| Pharmacally
Kither Biotech reported positive Phase 1 results for inhaled KIT2014, showing favorable safety, tolerability, and no measurable systemic exposure in healthy participants, supporting further development in COPD, non-CF bronchiectasis, and cystic fibrosis. Written By: Dr. Preethi Putti, PharmD Reviewed By: Pharmacally Editorial Team Kither Biotech has completed a Phase 1 clinical trial evaluating KIT2014, an investigational inhaled therapy for chronic respiratory diseases.
Open in Who Shared Issue with article?

Chugai Files New Drug Application in Japan for Sparsentan in IgA Nephropathy

| Pharmacally
Chugai has submitted an NDA in Japan for sparsentan to treat IgA nephropathy. The filing is supported by Japanese Phase III and global PROTECT trial data showing significant proteinuria reduction and long-term kidney protection. Written By: Nalam Karthik, PharmD Reviewed By: Pharmacally Editorial Team Chugai Pharmaceutical Co., Ltd.
Open in Who Shared Issue with article?

Sanofi Wins Japan Approval for Subcutaneous Sarclisa in Multiple Myeloma

| Pharmacally
Japan has approved Sanofi’s subcutaneous Sarclisa (isatuximab) for newly diagnosed and relapsed/refractory multiple myeloma, supported by Phase 3 IRAKLIA data showing efficacy comparable to intravenous administration with fewer administration-related reactions.
Open in Who Shared Issue with article?

Johnson & Johnson Reports Positive MEMBRANE Trial Results Demonstrating Reduced Chronic Subdural Hematoma Recurrence with MMA Embolization

| Pharmacally
The MEMBRANE trial published in JAMA Neurology showed that middle meningeal artery embolization with TRUFILL n-BCA reduced chronic subdural hematoma recurrence and repeat interventions by 47% compared with standard care alone.
Open in Who Shared Issue with article?

uniQure Reports Positive Data for AMT-260 in Drug-Resistant Epilepsy

| Pharmacally
uniQure’s AMT‑260 gene therapy showed seizure reductions up to 100% in early GenTLE trial data for refractory mesial temporal lobe epilepsy, supporting continued clinical evaluation. Written By: Farha Farheen, PharmD Reviewed By: Pharmacally Editorial Team uniQure N.V. has reported initial six-month follow-up data from the first low-dose cohort of its ongoing Phase I/IIa GenTLE trial evaluating AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy (MTLE).
Open in Who Shared Issue with article?

Japan Approves Avastin as First-Ever Therapy for Neurofibromatosis Type 2

| Pharmacally
Japan’s MHLW approves Avastin® (bevacizumab) as the first-ever therapy for Neurofibromatosis Type 2, offering patients a non-surgical option to preserve hearing and slow tumor progression. Written By: Chikkula Pavan Kumar, PharmD Reviewed By: Pharmacally Editorial Team Chugai Pharmaceutical Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved an additional indication for Avastin® (bevacizumab) for the treatment of Neurofibromatosis Type 2 (NF2).
Open in Who Shared Issue with article?

Pharmacally Journalists

Londhe, Vikas